NCT00360685View on ClinicalTrials.gov

Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX

NACompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
MucositisGraft-versus-host Disease
Interventions
DRUG

Tac+MTX

Tacrolimus- 0.03mg/kg/24h IV beginning day-3 Methotrexate- 15mg/m2 IV day +1 then 10mg/m2 IV on days 3, 6, 11 post transplant.

DRUG

TAC + MMF

Tacrolimus- 0.03 mg/kg/24h as a continuous IV infusion, beginning day -3. Mycophenolate Mofetil- 30 mg/kg/day IV in 2 divided doses (q12 hours) beginning day 0 at least 2 hours after the end of the hematopoietic stem cell transplant

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

All Listed Sponsors
lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT00360685 - Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX | Biotech Hunter | Biotech Hunter